Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ProSolus, Inc. is a wholly owned subsidiary of Canoa, Inc. We are focused on formulating and developing high-barrier-to-entry Transdermal Drug Delivery systems (TDDs) for ANDA, NDA, and 505(b)(2) applications. Our state-of-the art pharma facility in Miami, Florida is managed by a seasoned leadership team with more than 65 years of experience. With a manufacturing wing and 50 million+ transdermal and/or topical patch capaci...
ProSolus, Inc. is a wholly owned subsidiary of Canoa, Inc. We are focused on formulating and developing high-barrier-to-entry Transdermal Drug Delivery systems (TDDs) for ANDA, NDA, and 505(b)(2) applications. Our state-of-the art pharma facility in Miami, Florida is managed by a seasoned leadership team with more than 65 years of experience. With a manufacturing wing and 50 million+ transdermal and/or topical patch capacity, ProSolus effectively and efficiently delivers results. Our team is with you from the formulation stage, through the clinical stage, to the coating stage completing the cycle and preparing the product for packaging.

List your booth number for exhibitions, ask us